Dramatic secukinumab-mediated improvements in refractory leprosy-related neuritis via the modulation of T helper 1 (Th1) and T helper 17 (Th17) immune pathways

• Autor(a) principal: Kurizky,Patrícia Shu
• Data de Publicação: 2021
• Outros Autores: Motta,Jorgeth de Oliveira Carneiro da, Bezerra,Natanael Victor Furtunato, Sousa,Marcia Carolline dos Santos, Corazza,Danilo, Borges,Tatiana Karla dos Santos, Gomes,Ciro Martins
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Revista da Sociedade Brasileira de Medicina Tropical
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822021000100728
• topic: Leprosy; Interleukin-17; Neuritis

Abstract A 39-year-old woman was diagnosed with relapsed multibacillary leprosy and refractory neuritis. Here, we describe an evident loss of therapeutic effectiveness after the third pulse of corticosteroids, which may be attributed to tachyphylaxis and the posterior modulation of interferon- γ (IFN-γ), tumor necrosis factor- α (TNF-α,) interleukin-17A (IL-17A), and IL-12/23p40 after the induction phase of secukinumab. In this case, plasma cytokine analysis showed that secukinumab induced a reduction in IL-17 concomitant with impressive clinical improvements in the patient’s neural function. Interestingly, secukinumab induced reductions in cytokines related to Th1 responses and earlier stages of the Th17 response, including IL-23/12.